 SAN DIEGO, April 07, 2021 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals, Inc. Nasdaq: CRNX, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 4,562,044 shares of its common stock at a price to the public of 16.44 per share. All of the shares to be sold in the offering are being sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately 75.0 million. The offering is expected to close on or about April 12, 2021, subject to the satisfaction of customary closing conditions. 